Eylea biosimilars comparison

Biosimilars

Compare aflibercept biosimilars to brand Eylea for wet AMD and DME. Several biosimilars have been FDA-approved, offering potential cost savings for retinal anti-VEGF therapy.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
Eylea (reference)RegeneronIntravitreal injectionEvery 4–8 weeksOriginal reference product; extensive retinal disease data
Yesafili (aflibercept-jbvf)Samsung BioepisIntravitreal injectionEvery 4–8 weeksFDA-approved aflibercept biosimilar
Byooviz (ranibizumab-nuna)Samsung BioepisIntravitreal injectionMonthlyRanibizumab (Lucentis) biosimilar: alternative anti-VEGF option
Cimerli (ranibizumab-eqrn)CoherusIntravitreal injectionMonthlyRanibizumab biosimilar; interchangeable

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.